Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.49 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5827808 | 0.85 | SIRT2 (0.64) | SIRT2SIRT1SIRT3HSD17B10KDM4E | |
| SCHEMBL31480901 | 0.80 | RAB9A (0.50) | SIRT2SIRT1SIRT3HSD17B10KDM4E | |
| SCHEMBL4027801 | 0.78 | RAB9A (0.57) | SIRT2SIRT1SIRT3HSD17B10KDM4E | |
| SCHEMBL2995600 | 0.75 | MAPT (0.67) | SIRT2SIRT1SIRT3HSD17B10KDM4E | |
| SCHEMBL5827711 | 0.74 | PDCD1 (0.38) | RAB9ANPC1ALDH1A1 | |
| SCHEMBL707407 | 0.72 | CA12 (0.67) | KDM4ESMN1; SMN2MAPTRAB9AALDH1A1 | |
| SCHEMBL5828261 | 0.72 | ALDH1A1 (0.45) | SIRT1HSD17B10ALDH1A1 | |
| SCHEMBL29394052 | 0.71 | RAB9A (0.73) | SIRT2SIRT1SIRT3HSD17B10KDM4E | |
| SCHEMBL1640023 | 0.71 | RAB9A (0.73) | SIRT2SIRT1SIRT3HSD17B10KDM4E | |
| SCHEMBL4079402 | 0.70 | CA12 (0.56) | SIRT2SMN1; SMN2MAPTL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7153875-B2 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | INCYTE SAN DIEGO (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1385465-A4 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | INCYTE SAN DIEGO INC (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1385465-A2 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | Incyte San Diego, Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20020143182-A1 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | INCYTE GENOMICS, INC. | 2002-10-03 | — | — | US | disclosed |
| WO-2002072009-A2 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES | MAXIA PHARMACEUTICALS, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143182-A1 | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases | CCNY, HRAS, AHR | SIRT2 3053/4885SIRT1 3400/4885SIRT3 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.